drugset / Trial / NCT00446004

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

NCT00446004

Phase 1 Completed 15 enrolled University of Pittsburgh Novartis · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This is a research study that will investigate the effects of proton pump inhibitors (often used to treat stomach upset) on Gleevec® (a drug that is FDA-approved to treat some types of cancer) in healthy volunteers. Twelve healthy volunteers (six men and six women) will be recruited to complete the study. This research study will compare Gleevec® in the body when taken with and without proton pump inhibitors (PPI). Each volunteer will receive a 400 mg pill of Gleevec® on two occasions. On one occasion they will take the dose of Gleevec® alone (without PPI). On another occasion, they will take the Gleevec® after taking 40 mg of PPI daily by mouth for six days. Several blood samples will be drawn to measure the concentrations of Gleevec® and its breakdown products in the blood, with and without the influence of PPI.

Timeline

Start
2007-04
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 400 mg Oral
Subject Omeprazole Other / unclassified 40 mg Oral

Indications

No indication recorded.